Cobolimab is a Monoclonal Antibody owned by GSK, and is involved in 7 clinical trials, which are ongoing.
Cobolimab inhibits T cell immunoglobulin mucin-3 (TIM-3) that regulates macrophage activation. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. Tim-3 mRNAs are over expressed in cancers cells. The drug candidate by blocking the TIM-3, promotes anti tumor immunity and suppresses the tumor propagation.
The revenue for Cobolimab is expected to reach a total of $721m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Cobolimab NPV Report.
Cobolimab is under development for the treatment of solid tumors including melanoma, non-small cell lung cancer, metastatic hepatocellular carcinoma and colorectal cancer. It inhibits T cell immunoglobulin mucin-3 (TIM-3). The drug candidate is a humanized monoclonal IgG4 antibody and is administered through intravenous route. It is based on the (somatic hypermutation) SHM-XEL technology.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.
Quick View – Cobolimab
|Highest Development Stage|